AUTL Autolus Therapeutics ADS

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

LONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the Jefferies Global Healthcare Conference in London.

Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Tuesday, November 18, 2025 at 7:30am EST / 12:30pm GMT.

A webcast of the fireside chat will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at . A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Autolus Therapeutics plc

Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit .

Contact:

Amanda Cray 

 

 



EN
13/11/2025

Underlying

AUTLAutolus Therapeutics ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Autolus Therapeutics ADS

 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics to Participate in the Jefferies Global Healthcare...

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London LONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the Jefferies Global Healthcare Conference in London. Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Tuesday, November 18, 2025 at 7:30am EST / 12:30pm GMT. A webcast of th...

9h / 38m 1 EN
Mathijs Geerts Danau
  • Mathijs Geerts Danau
AUTL Autolus Therape...

Autolus Launch continues, FY25 beat is within reach

Autolus reported 3Q25 sales of $ 21.1m which came in slightly below CSS expectations of $ 21.9m. However, deferred revenue of $ 7.6m was significantly higher than the previous quarter giving us confidence that FY25 expectations are achievable. Additionally, at ASH 2025 Autolus plans to present longer follow-up in SLE and initial data in pediatric ALL, the topline results indicate a competitive profile against Kymriah. Autolus reiterated its plans to start a pivotal study in LN and a phase 1 in A...

AUTL AUTOLUS THERAPEUTICS ADS
22h / 39m 22h / 39m 1 EN
Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Mathijs Geerts Danau
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi
SOLB SOLVAY SA
AGFB AGFA-GEVAERT NV ... (+10)

Morning Notes : AGN NA, AGFB BB, IVA FP, MDXH BB, MELE BB, SOLB BB, DE...

: AGN NA, AGFB BB, IVA FP, MDXH BB, MELE BB, SOLB BB, DEME BB, AUTL US, ZEAL DC, PHVS US

SOLB SOLVAY SA
AGFB AGFA-GEVAERT NV
ZLDPF ZEALAND PHARMA A/S
MELE MELEXIS NV
IVA INVENTIVA SA
AUTL AUTOLUS THERAPEUTICS ADS
PHVS PHARVARIS NV
DEME DEME GROUP NV
AGN AEGON N.V.
MDXH MDXHEALTH
22h / 45m 22h / 45m 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and ...

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of targetClinical execution and data generation to support market growth and expansion continues; data in severe refractory systemic lupus erythematosus (srSLE) show no ICANS or high-grade CRS, demonstrate achievement of definition of remission in SLE (DORIS) in 83% (n=5/6) of patients and complete renal response (CRR) in 50% (n=3/6) of patientsLeaders...

November 12, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
GLPG GALAPAGOS NV
AUTL Autolus Therape... ... (+3)

ASH abstracts: Autolus, Galapagos, MaaT

The abstracts for presentations at the American Society of Haematology conference (ASH, 6-9 December) became available yesterday during the day (HERE). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (new data for Aucatzyl in paediatric ALL, real world data in adult ALL, amongst others), Galapagos (additional CAR-T data in r/r MCL and r/r DLBCL) and MaaT (longer follow up from ...

GLPG GALAPAGOS NV
AUTL AUTOLUS THERAPEUTICS ADS
MAAT MAAT PHARMA SA
11/04/25 November 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch